|Table of Contents|

Role of Fusobacterium nucleatum in the development,diagnosis and treatment of colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3493-3497
Research Field:
Publishing date:

Info

Title:
Role of Fusobacterium nucleatum in the development,diagnosis and treatment of colorectal cancer
Author(s):
HUANG Ting1; 2; LI Peihua1; 2; CHEN Zhixiu1; 2; PU Shiming1; 2; 3; ZHOU Zuping1; 2; 3
1.College of Life Sciences,Guangxi Normal University,Guangxi Guilin 541006,China;2.Guangxi Universities Key Laboratory of Stem Cell and Biopharmaceutical Technology,Guangxi Guilin 541004,China;3.Biomedical Research Center of Guangxi Normal University,Guangxi Guilin 541004,China.
Keywords:
colorectal cancer; Fusobacterium nucleatum; oncogenic mechanism; tumor immune microenvironment
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2023.18.030
Abstract:
Colorectal cancer (CRC) has a high incidence and is difficult to cure.More and more evidence has shown that intestinal microbiota dysregulation is closely related to the occurrence and development of CRC.Fusobacterium nucleatum (Fn) has been identified as a pathogen in the intestinal microbiota,which may contribute to CRC.This article reviews the important mechanisms of CRC induced by Fn,including virulence factors,chronic inflammation,miRNA,immune regulation and intestinal metabolites,and describes the clinical value of Fn in the diagnosis and treatment,in order to provide a reference for the screening of novel tumor biomarkers and the development of novel immunotherapeutic targets.

References:

[1] SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
[2] GANESAN K,GUO S,FAYYAZ S,et al.Targeting programmed Fusobacterium nucleatum Fap2 for colorectal cancer therapy［J］.Cancers (Basel),2019,11(10):1592-1601.
[3] LIU W,ZHANG R,SHU R,et al.Study of the relationship between microbiome and colorectal cancer susceptibility using 16SrRNA sequencing［J］.Biomed Res Int,2020,2020:7828392.
[4] JANNEY A,POWRIE F,MANN EH.Host-microbiota maladaptation in colorectal cancer［J］.Nature,2020,585(7826):509-517.
[5] BARTOLINI I,RISALITI M,RINGRESSI MN,et al.Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer:Focus on short and long-term outcomes［J］.World J Gastroenterol,2020,26(20):2498-2513.
[6] NIE S,TIAN B,WANG X,et al.Fusobacterium nucleatum subspecies identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry［J］.J Clin Microbiol,2015,53(4):1399-1402.
[7] STOKOWA-SOLTYS K,WOJTKOWIAK K,JAGIELLO K.Fusobacterium nucleatum-friend or foe［J］.J Inorg Biochem,2021,224(11):1586.
[8] QUEEN J,DOMINGUE JC,WHITE JR,et al.Comparative analysis of colon cancer-derived Fusobacterium nucleatum subspecies:inflammation and colon tumorigenesis in murine models［J］.mBio,2022,13(1):e0299121.
[9] BRENNAN CA,GARRETT WS.Fusobacterium nucleatum - symbiont,opportunist and oncobacterium［J］.Nat Rev Microbiol,2019,17(3):156-166.
[10] BERBERT L,SANTOS A,MAGRO DO,et al.Metagenomics analysis reveals universal signatures of the intestinal microbiota in colorectal cancer,regardless of regional differences［J］.Braz J Med Biol Res,2022,55：e11832.
[11] GETHINGS-BEHNCKE C,COLEMAN HG,JORDAO HWT,et al.Fusobacterium nucleatum in the colorectum and its association with cancer risk and survival:a systematic review and Meta-analysis［J］.Cancer Epidemiol Biomarkers Prev,2020,29(3):539-548.
[12] XU C,FAN L,LIN Y,et al.Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization［J］.Gut Microbes,2021,13(1):1980347.
[13] ONO T,YAMAGUCHI T,TAKAO M,et al.Fusobacterium nucleatum load in MSI colorectal cancer subtypes［J］.Int J Clin Oncol,2022,27(10):1580-1588.
[14] LEE JB,KIM KA,CHO HY,et al.Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer［J］.Sci Rep,2021,11(1):20263.
[15] TJALSMA H,BOLEIJ A,MARCHESI JR,et al.A bacterial driver-passenger model for colorectal cancer:beyond the usual suspects［J］.Nat Rev Microbiol,2012,10(8):575-582.
[16] 宋德心,王伟东,高瑞祺,等.肠道菌群在结直肠癌发生发展和诊断治疗中的作用研究进展［J］.中国普通外科杂志,2022,31(04):527-536. SONG DX,WANG WD,GAO RQ,et al.Research progress on the role of intestinal microbiota in the development,diagnosis and treatment of colorectal cancer［J］.Chinese Journal of General Surgery，2022,31(04):527-536.
[17] KOSTIC AD,CHUN E,ROBERTSON L,et al.Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment［J］.Cell Host Microbe,2013,14(2):207-215.
[18] FARDINI Y,WANG X,TEMOIN S,et al.Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity［J］.Mol Microbiol,2011,82(6):1468-1480.
[19] RUBINSTEIN MR,BAIK JE,LAGANA SM,et al.Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/beta-catenin modulator Annexin A1［J］.EMBO Rep,2019,20(4):e47638.
[20] GUO P,TIAN Z,KONG X,et al.FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of CHK2［J］.J Exp Clin Cancer Res,2020,39(1):202.
[21] CASASANTA MA,YOO CC,UDAYASURYAN B,et al.Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration［J］.Sci Signal,2020,13(641):eaba9157.
[22] WU J,LI Q,FU X.Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity［J］.Transl Oncol,2019,12(6):846-851.
[23] RANJBAR M,SALEHI R,HAGHJOOY JAVANMARD S,et al.The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review［J］.Cancer Cell Int,2021,21(1):194.
[24] WU Y,WU J,CHEN T,et al.Fusobacterium nucleatum potentiates intestinal tumorigenesis in mice via a toll-like receptor 4/p21-activated kinase 1 cascade［J］.Dig Dis Sci,2018,63(5):1210-1218.
[25] BRENNAN CA,CLAY SL,LAVOIE SL,et al.Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression［J］.Gut Microbes,2021,13(1):1987780.
[26] LIU T,LIU D,GUAN S,et al.Diagnostic role of circulating miR-21 in colorectal cancer:a update meta-analysis［J］.Ann Med,2021,53(1):87-102.
[27] YANG Y,WENG W,PENG J,et al.Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappa B,and up-regulating expression of microRNA-21［J］.Gastroenterology,2017,152(4):851-866.
[28] ZENG C,HUANG W,LI Y,et al.Roles of METTL3 in cancer:mechanisms and therapeutic targeting［J］.Journal of Hematology & Oncology,2020,13(1):117.
[29] XU Q,LU X,LI J,et al.Fusobacterium nucleatum induces excess methyltransferase-like 3-mediated microRNA-4717-3p maturation to promote colorectal cancer cell proliferation［J］.Cancer Sci,2021,13(1):1980347.
[30] PANSY K,UHL B,KRSTIC J,et al.Immune regulatory processes of the tumor microenvironment under malignant conditions［J］.Int J Mol Sci,2021,22(24):1331-1382.
[31] LIN X,WANG S,SUN M,et al.miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization［J］.J Hematol Oncol,2019,12(1):20.
[32] YANG C,DOU R,WEI C,et al.Tumor-derived exosomal microRNA-106b-5p activates EMT-cancer cell and M2-subtype TAM interaction to facilitate CRC metastasis［J］.Mol Ther,2021,29(6):2088-2107.
[33] FATHI M,PUSTOKHINA I,KUZNETSOV SV,et al.T-cell immunoglobulin and ITIM domain,as a potential immune checkpoint target for immunotherapy of colorectal cancer［J］.IUBMB Life,2021,73(5):726-738.
[34] KIM D,YOO SA,KIM WU.Gut microbiota in autoimmunity:potential for clinical applications［J］.Arch Pharm Res,2016,39(11):1565-1576.
[35] VANDER HEIDEN MG,CANTLEY LC,THOMPSON CB.Understanding the Warburg effect:the metabolic requirements of cell proliferation［J］.Science,2009,324(5930):1029-1033.
[36] LIN S,ZHANG X,ZHU X,et al.Fusobacterium nucleatum aggravates ulcerative colitis through promoting gut microbiota dysbiosis and dysmetabolism［J/OL］.(2022-09-11)［2022-12-04］.https://pubmed.ncbi.nlm.nih.gov/36088655/.aspx.DOI:10.1002/JPEP.22-0205.
[37] TERNES D,TSENKOVA M,POZDEEV VI,et al.The gut microbial metabolite formate exacerbates colorectal cancer progression［J］.Nat Metab,2022,4(4):458-475.
[38] HUH JW,ROH TY.Opportunistic detection of Fusobacterium nucleatum as a marker for the early gut microbial dysbiosis［J］.BMC Microbiol,2020,20(1):208.
[39] GUO S,LI L,XU B,et al.A simple and novel fecal biomarker for colorectal cancer:ratio of fusobacterium nucleatum to probiotics populations,based on their antagonistic effect［J］.Clin Chem,2018,64(9):1327-1337.
[40] YU T,GUO F,YU Y,et al.Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy［J］.Cell,2017,170(3):548-563.
[41] HUANG X,HONG X,WANG J,et al.Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis［J］.EBioMedicine,2020,61(10):3037-3053.
[42] BRENNAN CA,NAKATSU G,GALLINI COMEAU CA,et al.Aspirin modulation of the colorectal cancer-associated microbe Fusobacterium nucleatum［J］.mBio,2021,12(2):e00547.
[43] DENG F,ZHOU R,LIN C,et al.Tumor-secreted dickkopf2 accelerates aerobic glycolysis and promotes angiogenesis in colorectal cancer［J］.Theranostics,2019,9(4):1001-1014.
[44] HONG J,GUO F,LU SY,et al.F.nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer［J］.Gut,2021,70(11):2123-2137.
[45] GAO Y,BI D,XIE R,et al.Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer［J］.Signal Transduct Target Ther,2021,6(1):398.

Memo

Memo:
National Natural Science Foundation of China(No.81972700， 61827819，32260188）；国家自然科学基金（编号：81972700， 61827819，32260188）
Last Update: 1900-01-01